Megumu Osaki

Megumu Osaki

Auto-generated profile, based on publicly available information

Megumu Osaki

Department of Internal Medicine, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan,

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in Investigational New Drugs
Verified
Journal Article
Closed access
PDF file
MOMegumu Osaki
Megumu Osaki
RTRyo Tachikawa
Ryo Tachikawa
JOJunichiro Ohira
Junichiro Ohira
SHShigeo Hara
Shigeo Hara
KTKeisuke Tomii
Keisuke Tomii

23 January 2023 in Oncology
Verified
Journal Article
Closed access
PDF file
MOMegumu Osaki
Megumu Osaki
TAToru Arai
Toru Arai
HSHiromitsu Sumikawa
Hiromitsu Sumikawa
TTTakayuki Takimoto
Takayuki Takimoto
NTNaoko Takeuchi
Naoko Takeuchi
YIYoshikazu Inoue
Yoshikazu Inoue
Introduction: Pleuroparenchymal fibroelastosis (PPFE) findings are associated with poor prognosis in interstitial lung disease (ILD). However, the effect of PPFE findings on the development of immune checkpoint inhibitor-related pneumonitis (ICI-pneumonitis), a life-threatening adverse event, in lung cancer patients with ILD has not been elucidated. We aimed to determine whether PPFE findings are a risk factor for ICI-pneumonitis in lung cancer patients with ILD. Methods: We retrospectively examined 712 lung cancer patients, including 173 patients with background ILDs, who received ICI therapy in our institute between December 2015 and May 2021. Background ILDs were radiologically classified into three types: lone PPFE, other ILDs with PPFE, and other ILDs without PPFE. The cumulative ICI-pneumonitis incidence curves and median overall survival (mOS) were compared between the three radiological types, and risk factors for ICI-pneumonitis were evaluated. Results: Of 173 eligible patients with ILD, 23 patients (13.3%) experienced ICI-pneumonitis. The Kaplan-Meier method and the log-rank test showed that lone PPFE patients had significantly lower incidence of ICI-pneumonitis (p = 0.024) and longer mOS (575 vs. 326 days; p = 0.0096) than other ILDs patients. ICI-pneumonitis (p = 0.35) and mOS (p = 0.29) were not significantly different between other ILDs with and without PPFE. A multivariate Cox proportional hazards regression analysis revealed that lone PPFE pattern was an independent predictive factor for ICI-pneumonitis (hazard ratio, 0.20; 95% confidence interval, 0.043–0.93; p = 0.040). Conclusion: ICI therapy could be safer in lone PPFE patients than in other ILDs patients with lung cancer.

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
MOMegumu Osaki
Megumu Osaki
RTRyo Tachikawa
Ryo Tachikawa
YSYusuke Shima
Yusuke Shima
YSYuri Shimada
Yuri Shimada
AMAtsushi Matsunashi
Atsushi Matsunashi
KTKeisuke Tomii
Keisuke Tomii
Background: Serum levels of KL-6 are useful biomarkers for diagnosis of interstitial lung diseases (ILDs). However, its diagnostic utility in the setting of acute respiratory failure (ARF) is unknown. Aims and Objectives: We investigated how high serum KL-6 levels contributed to the differential diagnosis of ARF. Methods: We retrospectively examined consecutive 138 patients who were admitted to our department for the treatment of ARF with bilateral pulmonary infiltrates and were evaluated for serum KL-6 levels, from April 2015 to July 2018. Patients with apparent preexisting pulmonary fibrosis were excluded. Results: KL-6 values were high (≥ 500 U/mL) in 52 patients. Pulmonary diseases responsible for high KL-6 levels were detected in all patients of the high KL-6 group; ILDs associated with connective tissue diseases in 11 patients, latent chronic ILDs in 10 patients, drug-induced ILDs in 9 patients, pneumocystis pneumonia in 5 patients, radiation pneumonitis in 4 patients, and other etiologies in 13 patients. These KL-6-elevating diseases were the direct causes of ARF in 40 (77%) patients in the high KL-6 group compared to 22 (26%) patients in the normal KL-6 group (p <0.0001). The causes of ARF in the high KL-6 group were characterized by a lower proportion of bacterial pneumonia (10 [19%] vs 44 [51%] patients; p <0.0003), and a higher proportion of diseases for which corticosteroid therapy was indicated (32 [62%] vs 23 [27%] patients; p <0.0001). Conclusions: In ARF with bilateral pulmonary shadows and no apparent chronic fibrotic lesions, elevated serum KL-6 levels could be a marker of causative diseases other than bacterial pneumonia that often require steroid therapy.